SCHEMBL20460640

SCHEMBL20460640

COC(=O)CN1CCC(Nc2ncc(F)c(-c3cnc4ccccn34)n2)CC1

nearest known ligand 0.58

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
▸ MAPK10 P53779 3/20 0.58
▸ IRAK4 Q9NWZ3 2/20 0.58
▸ CDK2 P24941 10/20 0.57
▸ MAPK8 P45983 6/20 0.57
▸ MAPK9 P45984 5/20 0.57
▸ JUN P05412 3/20 0.57
▸ IGF1R P08069 13/20 0.54
▸ KCNH2 Q12809 4/20 0.45
▸ INSR P06213 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31500952 0.87 CDK2 (0.53) MAPK10IRAK4CDK2MAPK8MAPK9
SCHEMBL22228694 0.84 CDK2 (0.62) MAPK10IRAK4CDK2MAPK8MAPK9
SCHEMBL22228710 0.84 MAPK8 (0.53) MAPK10IRAK4CDK2MAPK8MAPK9
SCHEMBL20468460 0.83 CDK2 (0.56) MAPK10IRAK4CDK2MAPK8MAPK9
SCHEMBL31500965 0.83 CDK2 (0.56) MAPK10IRAK4CDK2MAPK8MAPK9
SCHEMBL20455526 0.82 CDK2 (0.58) MAPK10IRAK4CDK2MAPK8MAPK9
SCHEMBL31500996 0.82 CDK2 (0.58) MAPK10IRAK4CDK2MAPK8MAPK9
SCHEMBL22228853 0.81 CDK2 (0.59) MAPK10IRAK4CDK2MAPK8MAPK9
SCHEMBL31500962 0.81 CDK2 (0.59) MAPK10IRAK4CDK2MAPK8MAPK9
SCHEMBL22228927 0.81 CDK2 (0.51) MAPK10IRAK4CDK2MAPK8MAPK9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3577116-B1 DERIVATIVES OF N-CYCLOALKYL/HETEROCYCLOALKYL-4-(IMIDAZO[1,2-A]PYRIDINE)PYRIMIDIN-2-AMINE AS THERAPEUTIC AGENTS CHANGZHOU QIANHONG BIO PHARMA CO LTD (CN) 2025-04-23 — — EP disclosed
US-11111245-B2 Derivatives of N-cycloalkyl/heterocycloalkyl-4-(imidazo[1,2-a]pyridine)pyrimidin-2-amine as therapeutic agents AUCENTRA THERAPEUTICS PTY LTD (AU) 2021-09-07 — — US disclosed
US-11111245-B2 Derivatives of N-cycloalkyl/heterocycloalkyl-4-(imidazo[1,2-a]pyridine)pyrimidin-2-amine as therapeutic agents AUCENTRA THERAPEUTICS PTY LTD (AU) 2021-09-07 — — US disclosed
US-20200231586-A1 DERIVATIVES OF N-CYCLOALKYL/HETEROCYCLOALKYL-4-(IMIDAZO[1,2-a]PYRIDINE)PYRIMIDIN-2-AMINE AS THERAPEUTIC AGENTS AUCENTRA THERAPEUTICS PTY LTD (AU) 2020-07-23 — — US disclosed
US-20200231586-A1 DERIVATIVES OF N-CYCLOALKYL/HETEROCYCLOALKYL-4-(IMIDAZO[1,2-a]PYRIDINE)PYRIMIDIN-2-AMINE AS THERAPEUTIC AGENTS AUCENTRA THERAPEUTICS PTY LTD (AU) 2020-07-23 — — US disclosed
WO-2018141002-A2 DERIVATIVES OF N-CYCLOALKYL/HETEROCYCLOALKYL-4-(IMIDAZO [1,2-a]PYRIDINE)PYRIMIDIN-2-AMINE AS THERAPEUTIC AGENTS UNIVERSITY OF SOUTH AUSTRALIA (AU) 2018-08-09 — — WO disclosed
WO-2018141002-A2 DERIVATIVES OF N-CYCLOALKYL/HETEROCYCLOALKYL-4-(IMIDAZO [1,2-a]PYRIDINE)PYRIMIDIN-2-AMINE AS THERAPEUTIC AGENTS UNIVERSITY OF SOUTH AUSTRALIA (AU) 2018-08-09 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200231586-A1 DERIVATIVES OF N-CYCLOALKYL/HETEROCYCLOALKYL-4-(IMIDAZO[1,2-a]PYRIDINE)PYRIMIDIN-2-AMINE AS THERAPEUTIC AGENTS CDK2, CDKL1, CDKL2 MAPK10 411/4885IRAK4 1097/4885CDK2 1/4885
US-11111245-B2 Derivatives of N-cycloalkyl/heterocycloalkyl-4-(imidazo[1,2-a]pyridine)pyrimidin-2-amine as therapeutic agents CDK2, CDKL1, CDKL2 MAPK10 411/4885IRAK4 1097/4885CDK2 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback